Celator Pharmaceuticals Inc CPXX shares are trading higher by $7.40 at $5.72 in Tuesday's session. The catalyst for the monster rally is positive results from a Phase 3 trial for Vyexos in patients with high risk acute Myeloid Leukemia.
After a higher open, it rallied another $0.21 to $8.40 before some profit-takers came in. The new all-time high was was considerably above its former all-time high that was made in the first month of its IPO (September 2013) at $6.
Interestingly, the issue had a nice bump in volume in Monday's session ahead of the announcement with 8.6 million shares changing hands compared with its 20-day average of 2.1 million. With just under four hours remaining, 26 million shares have traded in today's session.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
